Effects of Vitamin D, Epigallocatechin Gallate, Vitamin B6, and D-Chiro-inositol Combination on Uterine Fibroids

NCT ID: NCT05409872

Last Updated: 2025-03-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-15

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized (1:1) double-blind, single-center controlled trial to evaluate the efficacy of 3 months of treatment with Epigallocatechin gallate, vitamin D, D-Chiro-inositol, and vitamin B6 on symptoms related to uterine fibroids

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A randomized controlled trial aimed to evaluate the efficacy of a combination of Epigallocatechin gallate, vitamin D3, D-Chiro-inositol, and vitamin B6 as a treatment for uterine fibroids. The clinical study is double-blind, neither patients nor investigators know whether the subject receives the combination of Epigallocatechin gallate, vitamin D, D-Chiro-inositol, and vitamin B6 or the placebo. After 3 months of treatment, changes in symptoms associated with uterine fibroids, quality of life, and ultrasounds characteristics are compared between the two treatment arms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leiomyoma, Uterine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized (1:1) double-blind, single-center controlled trial
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol

The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.

Group Type EXPERIMENTAL

Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol

Intervention Type DIETARY_SUPPLEMENT

The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.

Placebo

The subject takes the placebo twice a day for three months

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

The subject takes the placebo twice a day for three months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol

The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.

Intervention Type DIETARY_SUPPLEMENT

Placebo

The subject takes the placebo twice a day for three months.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women with multiple fibroids or single fibroma with a diameter ≥ 4 cm who are candidates for hysterectomy.
* Women with multiple fibroids or single fibroma with a diameter ≥ 4 cm who are candidates for myomectomy / uterine arterial embolization.
* Women with multiple fibroids or single fibroma with a diameter ≥ 4 cm who are candidates for treatment with magnetic resonance (MR)-guided Focused Ultra-Sound (MrgFUS).

Exclusion Criteria

* Pregnancy.
* Breastfeeding.
* Smoking.
* Suspected malignancy.
* Patients who have undergone medical treatment for uterine fibroids within the previous three months.
* Patients allergic to the components of the product or placebo under study.
* Patients who refuse to provide informed consent to participate in the study.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universita di Verona

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stefano Uccella

Prof.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stefano Uccella, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

AOUI Verona - University of Verona

Simone Garzon, MD

Role: PRINCIPAL_INVESTIGATOR

AOUI Verona - University of Verona

Pier Carlo Zorzato, MD

Role: PRINCIPAL_INVESTIGATOR

AOUI Verona - University of Verona

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AOUI Verona - University of Verona - Department of Obstetrics and Gynecology

Verona, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Stefano Uccella, MD, PhD

Role: CONTACT

0039 045 812 2720

Simone Garzon, MD

Role: CONTACT

0039 045 812 2720

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Simone Garzon, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Baird DD, Hill MC, Schectman JM, Hollis BW. Vitamin d and the risk of uterine fibroids. Epidemiology. 2013 May;24(3):447-53. doi: 10.1097/EDE.0b013e31828acca0.

Reference Type BACKGROUND
PMID: 23493030 (View on PubMed)

Roshdy E, Rajaratnam V, Maitra S, Sabry M, Allah AS, Al-Hendy A. Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study. Int J Womens Health. 2013 Aug 7;5:477-86. doi: 10.2147/IJWH.S41021. eCollection 2013.

Reference Type BACKGROUND
PMID: 23950663 (View on PubMed)

Porcaro G, Santamaria A, Giordano D, Angelozzi P. Vitamin D plus epigallocatechin gallate: a novel promising approach for uterine myomas. Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3344-3351. doi: 10.26355/eurrev_202003_20702.

Reference Type BACKGROUND
PMID: 32271452 (View on PubMed)

Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Rajaratnam V, Al-Hendy A. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil Steril. 2010 Oct;94(5):1887-93. doi: 10.1016/j.fertnstert.2009.08.065. Epub 2009 Oct 12.

Reference Type BACKGROUND
PMID: 19819432 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DEFIB

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Annatto-derived GG for Statin-associated Myopathy
NCT05312424 RECRUITING PHASE1/PHASE2
Fiber Fermentation Study
NCT04570137 COMPLETED NA
Lycopene in Healthy Male Participants
NCT00450957 COMPLETED PHASE1